Troponins and natriuretic peptides to detect cardiotoxicity: useful biomarkers or paradise lost?

Bračun, Valentina; Boer, Rudolf A. de

doi:10.1002/ejhf.1676

Cited by 2 publications

(1 citation statement)

References 22 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CV biomarkers have been used in patients with cancer to predict the risk and prognosis of cardiotoxicity, showing promising results [ 112 ]. The reverse rationale has also been suggested, reporting that certain tumour biomarkers could predict CVD severity and prognosis.…”

Section: Shared Prognostic Factorsmentioning

confidence: 99%

A new classification of cardio-oncology syndromes

et al. 2021

Self Cite

View full text Add to dashboard Cite

Increasing evidence suggests a multifaceted relationship exists between cancer and cardiovascular disease (CVD). Here, we introduce a 5-tier classification system to categorize cardio-oncology syndromes (COS) that represent the aspects of the relationship between cancer and CVD. COS Type I is characterized by mechanisms whereby the abrupt onset or progression of cancer can lead to cardiovascular dysfunction. COS Type II includes the mechanisms by which cancer therapies can result in acute or chronic CVD. COS Type III is characterized by the pro-oncogenic environment created by the release of cardiokines and high oxidative stress in patients with cardiovascular dysfunction. COS Type IV is comprised of CVD therapies and diagnostic procedures which have been associated with promoting or unmasking cancer. COS Type V is characterized by factors causing systemic and genetic predisposition to both CVD and cancer. The development of this framework may allow for an increased facilitation of cancer care while optimizing cardiovascular health through focused treatment targeting the COS type.

show abstract

Section: Shared Prognostic Factorsmentioning

confidence: 99%